
The royal who had a 'Hanoverian temper' and 'kicked a Corgi': Insider reveals the senior Windsor who couldn't handle his serious health crisis
The shocking incident occurred while George was receiving treatment for an arterial blockage in his right leg.
According to Hugo Vickers, who wrote a biography of the Queen Mother, the King faced a 'real danger of losing his leg' in 1949, but by December George was firmly on the road to recovery.
Nevertheless, he remained a 'difficult patient' during his time bedridden and proved 'hard to keep "amused and occupied"'.
It was while recovering that the King apparently became more irritable and aggressive.
Vickers said: 'His Hanoverian temper remained a problem. He had been known to kick a Corgi across the room at Windsor.'
Somewhat ironically, James Learmonth - the King's surgeon - had advised George to 'reduce the tempo of his life since thrombosis could occur if he was stressed either psychologically or physically', Vickers wrote.
George's wife, the then-Queen Elizabeth, nursed her husband throughout his health battle by taking on much of the burden of royal engagements while he recovered.
King George VI smoking a cigarette at a tennis match with Australian player G. L. Patterson. George was a lifelong smoker who allegedly puffed on 50 cigarettes a day, meaning he spent an estimated eight hours a day smoking
She also proved more than capable of calming her husband down when he lost his temper.
'During one of the King's "gnashes" Queen Elizabeth held the King's arm high, appearing to take his pulse, and saying "tick, tick, tick" to lighten the moment,' Vickers wrote.
Although the King's leg was saved, his health crisis was far from over as physicians faced the daunting task of making him cut down on cigarettes.
George was a lifelong smoker who allegedly went through 50 cigarettes a day, meaning the King spent an estimated eight hours a day smoking.
Tragically, his habit took a toll on his body, leading to a swift deterioration in his health in the final years of his reign.
This started to affect the King's ability to carry out his duties, with the heir to the throne - Princess Elizabeth - taking on more and more engagements.
By May 1951, the King was well enough to open the Festival of Britain, but afterwards he was forced to take an extended leave of absence.
This led to the cancellation of an official visit from the King of Norway just hours before he had been due to meet George.
In September that year, he had his left lung removed for was referred to at the time as 'structural abnormalities'.
However, in reality, it was due to cancer. The King's doctors kept this diagnosis both from the public and the monarch himself.
Although he did seem to be recovering from the procedure, the King died suddenly from a coronary thrombosis - or blood clot in an artery - five months later, in February 1952.
His death was a shock to the public and the Royal Family.
The King, in what would be his last public appearance, had seemed well when he waved off his eldest daughter at London Airport on January 31, 1952 as she and her husband, the Duke of Edinburgh, set off as his replacements on what was intended as a lengthy Commonwealth tour.
Joined by his wife and their younger daughter, Princess Margaret, the Royal Family said their goodbyes on the Tarmac before gathering on a rooftop to watch the plane take off.
Just six days later George passed away in his sleep.
News of her father's death, and her immediate accession to the throne, reached Elizabeth while she was on safari in Kenya.
King George VI (right), the then Queen Elizabeth and Princess Margaret wave farewell to Princess Elizabeth and the Duke of Edinburgh as they depart for a tour of the Commonwealth in January 1952. This would be George's last public appearance
The tour was abruptly cancelled as the new Queen, then aged 25, rushed back to London.
The unexpected nature of the King's death meant Elizabeth did not have a change of black clothes to mark his passing.
This led Queen Elizabeth II to add a new royal protocol that royals must always travel with a change of black clothes in the event of such a tragedy.
As the second son of George V, the King was a famously reluctant monarch who had acceded unexpectedly to the throne in December 1936 after the dramatic abdication of older brother Edward VIII.
Christened Albert after his great-grandfather Prince Albert in the last years of Queen Victoria's long reign, and known as 'Bertie' to his family and friends, George VI had been a shy and sickly child who suffered from a stutter and had always been content to live in the shadows of the more charismatic and glamorous Edward.
George went on to see the country through the darkest days of World War Two, which was the defining period of his reign.
When the Royal Family elected to stay in London for the majority of the war, their fortitude won them the enduring respect and affection of the British people. They even subjected themselves to food rationing and restrictions on the depth of their bathwater.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
13 minutes ago
- The Independent
Researchers find milk type that increases risk of heart disease and death
A 33-year study conducted in Norway has investigated the long-term health impacts of consuming full-fat versus low-fat milk. Researchers analysed health data from 73,860 individuals, finding that the fat content of milk influenced the risk of death from heart disease. The study revealed that individuals who consumed full-fat milk had a higher mortality risk compared to those who drank low-fat milk. Specifically, consuming low-fat milk was linked to an 11 per cent lower overall mortality risk and a 7 per cent reduced risk of cardiovascular disease compared to whole milk. These findings support current NHS health advice, which cautions against high intake of saturated fat found in full-fat dairy due to its link to increased cholesterol and heart disease risk.


BBC News
14 minutes ago
- BBC News
Daily weight loss pill helps patients lose 12% of body weight
Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The manufacturer, Eli Lilly, says the drug, which is not yet licensed, could be available next daily pill, called orforglipron, works by suppressing appetite and making you feel more results of a major trial show those on the highest dose lost an average of 12 kilos (nearly two stone) over 16 months but about one in 10 stopped taking the pills due to side effects, including nausea and vomiting. In addition to weight loss, participants also benefited from reductions in cholesterol, blood fats and blood Kenneth Custer of Eli Lilly said the company was planning to submit the drug for licensing before the end of the year and preparing for a "global launch to address this urgent pubic health need".So where might this weight loss pill fit in to the blockbuster multi-billion pound market dominated by injectable drugs like Mounjaro, Wegovy and Ozempic?The pill is much less effective than 12% weight loss achieved by those taking orforglipron compares to 22% weight loss for patients on Mounjaro, given by weekly injection. Both drugs are made by Eli Lilly. Despite being less effective, there is likely to be a significant market for weight loss pills, as a needle-free means of cutting obesity experts hope the oral drug will be far cheaper than current injectables which would make it available to many more patients. The full results of the trial will be presented next month at the European Association for the Study of Diabetes annual meeting and published in a peer-reviewed manufacturer, Novo Nordisk, also has an oral version of its injectable drug Wegovy which it has already submitted for approval in the trials, patients on the highest dose of the Novo Nordisk daily pill lost around 15% of their bodyweight after 64 weeks.


BBC News
14 minutes ago
- BBC News
Shrewsbury cancer charity ready for clinical trials of new drug
A Shropshire charity says it is ready to start clinical trials on a new drug to treat lung the charity Brightwater Research was formed in 2019, its founders have spent 15 years developing the drug Valoxydin, and said the results of initial testing had been manager David Crane said the drug was designed to prevent tumours spreading around the charity is currently seeking funding to fully develop the drug so it can eventually be used to treat patients. Decisions about which medicines are made available on the NHS are made by different organisations in England, Wales and are usuaully based on factors, including the evidence available about a drug and the length by which it could extend patients' from experts and public involvement is also considered. Mr Crane said Valoxydin was an anti-metastatic drug which targeted the formation of secondary tumours – also known as metastases - in the body and stopped the primary cancer from showed the drug could potentially reduce the spread of lung cancer by approximately 80% in animal models, he trustee Ted Youngman, whose father died with lung and brain cancer 15 years ago, said from the initial theory about how the treatment might work, they had begun to experiment with the drug in a petri dish and had gone through more than 50 variations to reach the point it was now at. 'Tremendous' "There's a lot of work still to go, but this is tremendous," Mr Youngman added: "It's much easier to stop [cancer] from spreading than it is to treat it once it's already spread."That's the approach we're taking, which we think is a bit different from other treatments before now."The charity's founders believe it might be possible the drug could be developed for use in the treatment of liver, kidney and bowel cancer, but added a significant amount of additional funding would be needed for further with potential large-scale backers had already begun, Mr Crane said the process could take two to three years, at which point it might be ready for consideration by the drug would be taken as a pill, which would mean it was relatively easy to administer to Crane said the drug would need to be taken daily for the rest of the patient's life – or until another solution is discovered. Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.